Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 1-Year High - Here's Why

Key Points

• Kiniksa Pharmaceuticals International (NASDAQ: KNSA) shares reached a new 52-week high of $34.78 during trading, with a market capitalization of $2.60 billion.
• Analysts have given Kiniksa a consensus rating of "Buy", with target prices ranging from $36.00 to $54.00.
• Insider trading revealed significant sales, with Director Thomas Malley selling over 78,000 shares, indicating a potential shift in insider sentiment.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as $34.69 and last traded at $34.78, with a volume of 37968 shares. The stock had previously closed at $34.28.

Wall Street Analyst Weigh In

KNSA has been the subject of several recent research reports. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Sunday. Wedbush reiterated an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Jefferies Financial Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Finally, Wells Fargo & Company boosted their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, July 9th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International has an average rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International Stock Performance

The business's 50-day moving average price is $30.95 and its 200-day moving average price is $26.54. The stock has a market cap of $2.65 billion, a P/E ratio of 892.97 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The firm had revenue of $156.80 million during the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Insider Buying and Selling

In other news, CAO Michael R. Megna sold 11,000 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $34.84, for a total transaction of $383,240.00. Following the transaction, the chief accounting officer directly owned 38,011 shares in the company, valued at approximately $1,324,303.24. This trade represents a 22.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mark Ragosa sold 18,889 shares of the stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $32.89, for a total transaction of $621,259.21. Following the transaction, the chief financial officer owned 27,009 shares in the company, valued at approximately $888,326.01. This represents a 41.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 558,403 shares of company stock worth $18,078,671 over the last three months. 53.48% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently modified their holdings of KNSA. Price T Rowe Associates Inc. MD boosted its stake in Kiniksa Pharmaceuticals International by 23.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,111 shares of the company's stock valued at $299,000 after acquiring an additional 2,881 shares in the last quarter. Voya Investment Management LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 16.8% in the fourth quarter. Voya Investment Management LLC now owns 19,988 shares of the company's stock worth $395,000 after buying an additional 2,870 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Kiniksa Pharmaceuticals International by 11.1% in the fourth quarter. Northern Trust Corp now owns 283,599 shares of the company's stock worth $5,610,000 after buying an additional 28,393 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Kiniksa Pharmaceuticals International by 2.2% in the fourth quarter. Bank of America Corp DE now owns 215,772 shares of the company's stock worth $4,268,000 after buying an additional 4,654 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth $256,000. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.